title: SCID-bg mice as xenograft recipients.
abstract: SCID-bg (scid/scid, beige/beige) is a strain of double-mutant mice with impaired lymphoid development and reduced natural killer (NK) cell activity. The present study was undertaken to evaluate the usefulness of SCID-bg mice as xenograft recipients. Fetal guinea pig tissues (liver, thymus, spleen) were transplanted under the kidney capsule of the mice and their serum guinea pig IgG levels were measured weekly thereafter, C.B.-17-scid and anti-asialo GM1 antiserum-treated (NK-depleted) C.B.-17-scid (C.B.-17-scid-AGM1) mice that received the identical transplants were used as controls. Throughout the experimental period (1, 2, and 3 weeks after transplantation), the average serum guinea pig IgG concentrations was highest in C.B.-17-scid-AGM1 mice followed by SCID-bg mice and lowest in C.B.-17-scid mice without antiserum treatment, though we could not find any statistical significance among these groups. However, SCID-bg mice always showed the smallest within-group variance (individual difference) in the serum guinea pig IgG concentrations (P < 0.05, versus C.B.-17-scid-AGM1 mice at 1, 2, and 3 weeks and versus C.B.-17-scid mice at 2 weeks). The graft size was not significantly different among these three groups, but the spleen grafts in C.B.-17-scid mice contained fewer nucleate cells than the other two groups. These results indicate that the reduced NK cell activity by beige mutation is not crucial for the success of xenogenic transplantation, though SCID-bg mice may be useful as xenograft recipients with a consistent potential to retain the viability and function of engrafted tissues.
authors.affiliation: Department of Veterinary Science, National Institute of Health, Tokyo, Japan. shibata@nih.go.jp
authors.forename: S
authors.initials: S
authors.lastname: Shibata
authors.forename: T
authors.initials: T
authors.lastname: Asano
authors.forename: A
authors.initials: A
authors.lastname: Ogura
authors.forename: N
authors.initials: N
authors.lastname: Hashimoto
authors.forename: J
authors.initials: J
authors.lastname: Hayakawa
authors.forename: K
authors.initials: K
authors.lastname: Uetsuka
authors.forename: H
authors.initials: H
authors.lastname: Nakayama
authors.forename: K
authors.initials: K
authors.lastname: Doi
mesh_terms: D000818:Animals; D005260:Female; D016332:Fetal Tissue Transplantation; D005677:G(M1) Ganglioside / Q000008:administration & dosage; D006084:Graft Rejection / Q000473:pathology; D006168:Guinea Pigs; D007074:Immunoglobulin G / Q000032:analysis; D007668:Kidney / Q000473:pathology / Q000601:surgery*; D007694:Killer Cells, Natural / Q000276:immunology; D016031:Liver Transplantation / Q000276:immunology / Q000473:pathology; D008297:Male; D051379:Mice; D016513:Mice, SCID / Q000276:immunology*; D013154:Spleen / Q000276:immunology / Q000473:pathology / Q000637:transplantation*; D013950:Thymus Gland / Q000276:immunology / Q000473:pathology / Q000637:transplantation*; D014183:Transplantation, Heterologous
chemical_list: D007074:Immunoglobulin G; D005677:G(M1) Ganglioside; C018835:asialo GM1 ganglioside